Recent News for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Date Title
Sep 18 Biohaven and Ra Pharma drugs selected for innovative ALS study
Sep 18 Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Sep 10 Biohaven completes enrollment in Phase 2/3 study of migraine med vazegepant
Sep 10 Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Sep 9 Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
Sep 4 Biohaven up 7% on accelerated rimegepant timeline
Aug 23 Biohaven Pharmaceutical: An Intriguing CNS Play
Aug 8 Biohaven Pharmaceuticals EPS misses by $3.40
Aug 8 Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
Aug 7 Biohaven hits enrollment target in late-stage study of rimegepant for migraine prevention
Aug 7 Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
Jul 31 Late-stage study underway for Biohaven's verdiperstat in MSA
Jul 31 Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
Jul 24 Release Your 'Inner Spock' When Investing in Biotech Stocks
Jul 22 35 Stocks Moving In Monday's Pre-Market Session
Jul 22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
Jul 22 FDA rejects Biohaven's Nurtec application for ALS
Jul 20 The Week Ahead In Biotech: Pharma Earnings Pick Up Pace
Jul 19 Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
Jul 19 Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
Jul 15 Biohaven up 5% on publication of late-stage data on migraine med Zydis
Jul 15 Biohaven reveals positive results in migrane drug trial
Jul 15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
Jul 11 Biohaven's rimegepant successful in third late-stage migraine study
Jul 11 Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Back to the Main BHVN Page...